Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Research Triangle Park › NPI 1215914288
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $115.71M by Medicaid between Jan 2018 and Dec 2024, across 236 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 47% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
RESEARCH TRIANGLE PARK, NC 27709
33aNPI1215914288assigned 12/29/2005
33bProvider typeClinical Medical Laboratory
28Total paid$115.71M
24GClaims5,070,325
24DCodes billed236
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#4 of 128
Median peer was paid$268K
This provider vs. median432×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018456,759$13.98M
2019488,505$13.90M
2020637,999$14.66M
2021822,993$20.14M
2022868,041$18.53M
2023969,386$18.80M
2024incomplete826,642$15.71M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 47% 1,534,376 1,028,989 $54.90M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 17% 346,543 244,798 $19.36M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 8.0% 154,063 99,637 $9.24M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 5.2% 59,123 50,126 $5.97M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 2.6% 10,272 9,204 $2.98M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 2.0% 5,273 4,801 $2.32M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1.3% 16,675 12,750 $1.55M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 1.2% 59,835 54,816 $1.44M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 1.2% 60,463 55,374 $1.37M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 43,346 39,539 $868K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 35,990 32,408 $728K
80348 <1% 136,181 106,890 $703K
224 more codes
80081 <1% 13,836 $657K
87086 Culture, bacterial; quantitative colony count, urine <1% 82,221 $455K
87902 <1% 2,877 $414K
80361 <1% 85,558 $392K
80346 <1% 36,644 $379K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 25,573 $360K
86480 <1% 8,508 $359K
84443 Thyroid stimulating hormone (TSH) <1% 35,171 $345K
80053 Comprehensive metabolic panel <1% 52,535 $332K
80354 <1% 90,772 $327K
86803 <1% 34,470 $321K
80359 <1% 77,848 $295K
80373 <1% 69,975 $289K
80347 <1% 67,761 $288K
80061 Lipid panel <1% 42,351 $285K
80365 <1% 79,229 $273K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 7,772 $272K
80372 <1% 67,816 $264K
80353 <1% 83,026 $262K
83036 Hemoglobin; glycosylated (A1C) <1% 44,824 $242K
81329 <1% 5,001 $232K
80358 <1% 78,359 $231K
80050 General health panel <1% 13,770 $223K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 44,416 $206K
80055 <1% 4,659 $186K
80324 <1% 43,831 $183K
86762 <1% 20,499 $183K
80362 <1% 27,723 $176K
80337 <1% 38,973 $175K
80349 <1% 33,971 $174K
86787 <1% 18,997 $169K
80338 <1% 38,551 $166K
87340 <1% 25,835 $163K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 4,338 $162K
87522 Neg quan hep c or qual rna <1% 5,775 $153K
87536 <1% 2,464 $150K
80326 <1% 38,960 $137K
80366 <1% 44,591 $130K
83992 <1% 43,342 $129K
80377 <1% 37,815 $129K
80370 <1% 40,961 $127K
80074 <1% 4,921 $123K
80367 <1% 39,425 $120K
80334 <1% 38,503 $117K
80371 <1% 38,951 $116K
80341 <1% 39,774 $111K
86850 <1% 20,592 $108K
82607 <1% 12,388 $106K
83020 <1% 13,943 $104K
80360 <1% 44,367 $103K
80331 <1% 37,819 $99K
80368 <1% 42,287 $91K
80364 <1% 38,982 $90K
85027 <1% 21,549 $87K
86780 <1% 9,378 $85K
86592 <1% 30,453 $84K
84439 <1% 14,972 $82K
82746 <1% 9,709 $81K
80357 <1% 37,765 $81K
36415 Collection of venous blood by venipuncture <1% 50,004 $80K
80344 <1% 37,986 $75K
87088 <1% 14,065 $73K
87150 <1% 2,971 $72K
83021 <1% 5,852 $68K
80321 <1% 8,431 $66K
87186 <1% 10,237 $65K
80325 <1% 3,707 $65K
82570 <1% 13,031 $57K
82728 <1% 6,930 $50K
81001 <1% 24,529 $49K
87077 <1% 8,748 $45K
81243 <1% 2,216 $45K
80355 <1% 36,999 $40K
86901 <1% 19,526 $40K
86900 <1% 19,531 $39K
81025 <1% 11,744 $38K
81596 <1% 1,867 $37K
86706 <1% 5,121 $35K
80356 <1% 6,066 $34K
84702 <1% 4,110 $33K
86696 <1% 2,395 $32K
85660 <1% 9,220 $32K
82105 <1% 3,657 $30K
84153 <1% 2,955 $30K
82043 <1% 8,511 $29K
84436 <1% 6,808 $28K
86704 <1% 3,902 $27K
87521 Neg quan hep c or qual rna <1% 1,111 $26K
84146 <1% 2,609 $25K
87081 <1% 4,991 $24K
82950 <1% 8,031 $24K
86361 <1% 1,999 $23K
80345 <1% 3,469 $22K
84479 <1% 5,135 $21K
86769 <1% 531 $20K
86695 <1% 2,325 $19K
80320 <1% 2,489 $19K
83550 <1% 3,866 $19K
86038 <1% 2,373 $19K
86708 <1% 2,476 $18K
84403 <1% 1,251 $17K
83540 <1% 4,904 $17K
87563 <1% 1,275 $17K
81003 <1% 10,795 $16K
87900 <1% 200 $15K
80374 <1% 2,592 $15K
80048 Basic metabolic panel (calcium, ionized) <1% 2,775 $14K
86735 <1% 1,557 $14K
83735 <1% 3,484 $14K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 208 $13K
86765 <1% 1,749 $13K
84156 <1% 5,388 $12K
82947 <1% 4,546 $11K
82248 <1% 4,279 $11K
84550 <1% 3,718 $10K
87535 <1% 357 $10K
84481 <1% 1,197 $9K
80369 <1% 2,430 $9K
86360 <1% 391 $9K
82565 <1% 3,454 $8K
85610 <1% 3,697 $8K
80076 <1% 1,381 $8K
84520 <1% 3,706 $8K
83615 <1% 2,284 $8K
82977 <1% 1,658 $8K
84703 <1% 1,694 $7K
86140 <1% 2,337 $7K
80164 <1% 1,026 $7K
84480 <1% 844 $7K
86317 <1% 978 $6K
86870 <1% 448 $6K
84450 <1% 2,399 $6K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 260 $6K
80323 <1% 883 $5K
86431 <1% 1,328 $5K
86003 <1% 55 $5K
85652 <1% 3,201 $5K
82247 <1% 2,250 $5K
84075 <1% 2,075 $5K
85730 <1% 1,453 $5K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 189 $5K
82040 <1% 2,115 $4K
86336 <1% 372 $4K
87481 <1% 143 $4K
83883 <1% 333 $4K
86705 <1% 503 $4K
82310 <1% 1,799 $4K
83010 <1% 332 $4K
82677 <1% 327 $4K
82172 <1% 302 $4K
83516 <1% 369 $4K
83690 <1% 894 $4K
82542 <1% 213 $4K
86709 <1% 573 $4K
86376 <1% 481 $4K
84100 <1% 1,461 $3K
84295 <1% 1,677 $3K
86235 <1% 49 $3K
86200 <1% 405 $3K
82435 <1% 1,689 $3K
84460 <1% 1,269 $3K
84155 <1% 1,836 $3K
86593 <1% 1,107 $3K
80375 <1% 1,171 $3K
86702 <1% 368 $3K
84402 <1% 225 $3K
84132 <1% 1,363 $3K
82550 <1% 380 $2K
82150 <1% 495 $2K
80178 <1% 594 $2K
82140 <1% 228 $2K
83970 <1% 137 $2K
83721 <1% 453 $2K
83880 <1% 123 $2K
87529 <1% 48 $2K
82652 <1% 111 $2K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 13 $2K
81401 <1% 26 $1K
82670 <1% 84 $1K
84144 <1% 94 $1K
84425 <1% 100 $1K
83013 <1% 25 $1K
86701 <1% 183 $1K
85018 <1% 746 $1K
83525 <1% 137 $1K
80363 <1% 28 $893.87
83655 <1% 75 $846.14
83001 <1% 59 $821.52
87350 <1% 114 $820.72
85014 <1% 579 $779.69
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 16 $769.65
86225 <1% 85 $703.96
80051 <1% 162 $686.32
80299 <1% 43 $682.64
86777 <1% 89 $667.51
82784 <1% 74 $632.21
87517 <1% 34 $601.83
87070 <1% 107 $585.91
82785 <1% 27 $431.81
85045 <1% 169 $404.54
86804 <1% 41 $389.61
83002 <1% 30 $341.19
80171 <1% 44 $326.83
87538 <1% 13 $311.75
86707 <1% 48 $293.46
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 41 $225.00
84207 <1% 14 $200.01
82533 <1% 12 $175.02
80047 <1% 13 $125.32
82465 <1% 70 $109.31
80305 <1% 13 $105.73
82103 <1% 14 $103.37
84478 <1% 24 $79.57
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 13 $65.04
82374 <1% 15 $37.02
87660 <1% 12 $35.19
87480 <1% 12 $34.99
87510 <1% 12 $34.99
86364 <1% 15 $33.90
85041 <1% 13 $22.97
85048 <1% 13 $19.65
85007 <1% 13 $12.84
83986 <1% 16 $7.58
RFUND 0% 64 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.